文献速递免疫规划卫生政策与健康促进妇幼与学校卫生

南非HIV感染与未感染孕妇产前流感疫苗接种的成本效果分析

A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa.
PubMed 文献 · Vaccine · 2019-09-28

该研究构建决策树模型模拟南非孕妇及<6月龄婴儿人群,比较优先接种HIV感染孕妇、不优先接种与不接种的社 会成本与健康产出。优先接种可避免9070例流感病例、411例住院和30例死亡,每获得一个QALY的社会成本为4689美元;不优先接种避免7801例病例,每QALY成本5924美元。结论认为产前流感疫苗接种可减轻流感影响并可能具有成本效果。

要点

  • 优先接种HIV感染孕妇可避免9070例流感病例、411例住院和30例死亡,避免比例为13.5%。
  • 不优先接种可避免7801例流感病例、335例住院和24例死亡,避免比例为11.6%。
  • 优先接种每QALY社会成本4689美元,不优先接种为5924美元,均低于南非2015年人均GDP 5724美元的阈值。

核心结论

  • 南非产前流感疫苗接种活动可减轻流感影响,并可能具有成本效果。

研究设计与样本

  • 研究使用TreeAge Pro Suite 2015构建决策树模型,模拟南非孕妇及<6月龄婴儿人群。
  • 模型评估优先接种HIV感染孕妇、不优先接种与不接种相比的社会成本和结局变化,并进行10000次蒙特卡洛模拟的概率敏感性分析,生成90%不确定性区间。
  • 成本效果阈值设为南非2015年人均国内生产总值5724美元。

主要发现

  • 优先接种避免孕妇和婴儿流感总病例9070例(90% UI:7407-11217),包括住院411例(90% UI:305-546)和死亡30例(90% UI:22-40),避免比例为13.5%(90% UI:9.0-20.5%)。
  • 不优先接种避免流感病例7801例(90% UI:6465-9527),包括住院335例(90% UI:254-440)和死亡24例(90% UI:18-31),避免比例为11.6%(90% UI:7.8-17.4%)。
  • 优先接种每获得一个QALY的社会成本为4689美元(90% UI:3128-7294美元),不优先接种为5924美元(90% UI:3992-9056美元)。

关键数值与推荐

  • 成本效果阈值采用南非2015年人均GDP 5724美元。
  • 优先接种避免比例13.5%(90% UI:9.0-20.5%),不优先接种避免比例11.6%(90% UI:7.8-17.4%)。
  • 优先接种每QALY成本4689美元(90% UI:3128-7294美元),不优先接种每QALY成本5924美元(90% UI:3992-9056美元)。

临床怎么用

  • 原文结论认为南非产前流感疫苗接种活动可减轻流感影响并可能具有成本效果,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant women and infants are at increased risk of severe disease from influenza. Antenatal influenza vaccination is safe and can reduce the risk of illness for women and their infants. We evaluated for South Africa the health effects of antenatal influenza vaccination among pregnant women and their infants aged <6 months old and assessed its cost-effectiveness. METHODS: We constructed a decision tree model to simulate the population of pregnant women and infants aged <6 months in South Africa using TreeAge Pro Suite 2015. The model evaluated the change in societal costs and outcomes associated with a vaccination campaign that prioritized HIV-infected over HIV-uninfected pregnant women compared with no vaccination. We also examined the impacts of a campaign without prioritization. Upper and lower 90% uncertainty intervals (90% UI) were generated using probabilistic sensitivity analysis on 10000 Monte Carlo simulations. The cost-effectiveness threshold was set to the 2015 per capita gross domestic product of South Africa, US$5724. RESULTS: Antenatal vaccination with prioritization averted 9070 (90% UI: 7407-11217) total cases of influenza among pregnant women and infants, including 411 (90% UI: 305-546) hospitalizations and 30 (90% UI: 22-40) deaths. This corresponds to an averted fraction of 13.5% (90% UI: 9.0-20.5%). Vaccinating without prioritization averted 7801 (90% UI: 6465-9527) cases of influenza, including 335 (90% UI: 254-440) hospitalizations and 24 (90% UI: 18-31) deaths. This corresponds to an averted fraction of 11.6% (90% UI: 7.8-17.4%). Vaccinating the cohort of pregnant women with prioritization had societal cost of $4689 (90% UI: $3128-$7294) per Quality Adjusted Life Year (QALY) gained while vaccinating without prioritization had a cost of $5924 (90% UI: $3992-$9056) per QALY. CONCLUSIONS: Antenatal influenza vaccination campaigns in South Africa would reduce the impact of influenza and could be cost-effective.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Biggerstaff M, Cohen C, Reed C, et al. A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa. Vaccine. 2019. PMID: 31575494. doi:10.1016/j.vaccine.2019.09.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。